Compare OSBC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSBC | SDGR |
|---|---|---|
| Founded | 1981 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2014 | 2020 |
| Metric | OSBC | SDGR |
|---|---|---|
| Price | $24.65 | $27.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $28.33 | $21.43 |
| AVG Volume (30 Days) | 495.0K | ★ 3.0M |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ 1.02 | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $14.40 | N/A |
| Revenue Next Year | $3.03 | $3.12 |
| P/E Ratio | $24.37 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $16.65 | $10.95 |
| 52 Week High | $26.06 | $33.78 |
| Indicator | OSBC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 52.63 |
| Support Level | $23.99 | $11.27 |
| Resistance Level | $25.95 | $31.59 |
| Average True Range (ATR) | 0.43 | 2.17 |
| MACD | -0.00 | -0.67 |
| Stochastic Oscillator | 50.00 | 20.64 |
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.